Topol is right — Parkinson's has no disease-modifying treatments yet, and it is the fastest-growing neurological disorder globally. The linked Nature review confirms this and outlines ongoing research into α-synuclein therapies and biomarkers. The one unverifiable claim is whether it's the 'second most common' neurodegenerative disease — the article emphasizes its rapid growth but doesn't rank it specifically. This is a factually grounded call to action backed by solid peer-reviewed evidence.